Sanno Bio Iteba peptide injection was approved for production and regarded as the first in China

Itebaptide is a platelet glycogen II.b/III.a inhibitor antagonist, which inhibits platelet aggregation through selective, reversible final common path, clinically used to treat acute coronary artery syndrome (unstable angina/non-ST segment elevation myocardial infarction), with rapid effect, strong anti-platelet effect, drug effect reversible and so on.
figure 1: 2015-2019 Sales of end-to-ethyba peptide injections in China's public medical institutions (units: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern Mi-Net data show that in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal growth rate of more than 200%.
figure 2: Eteba peptide injection consistency evaluation carried out (including new classification of production) Source: Mi net consistency evaluation database currently only Shenzhen Hanyu Pharmaceuticals submitted a supplementary application for Ideba peptide injection consistency evaluation, is still in review and approval;
。